CVE:NSP

Naturally Splendid Enterprises Competitors

C$0.06
0.00 (0.00 %)
(As of 04/12/2021 01:47 PM ET)
Add
Compare
Today's Range
C$0.06
Now: C$0.06
C$0.07
50-Day Range
C$0.06
MA: C$0.07
C$0.09
52-Week Range
C$0.03
Now: C$0.06
C$0.14
Volume45,346 shs
Average Volume1.16 million shs
Market CapitalizationC$13.08 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Naturally Splendid Enterprises (CVE:NSP) Vs. COV, EMH, IGX, QPT, CZO, and CTX

Should you be buying NSP stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Naturally Splendid Enterprises, including Covalon Technologies (COV), Emerald Health Therapeutics (EMH), IntelGenx Technologies (IGX), Quest PharmaTech (QPT), Ceapro (CZO), and Crescita Therapeutics (CTX).

Covalon Technologies (CVE:COV) and Naturally Splendid Enterprises (CVE:NSP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Earnings and Valuation

This table compares Covalon Technologies and Naturally Splendid Enterprises' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$23.84 million1.53C$-6,144,922.00C($0.24)-5.92
Naturally Splendid EnterprisesC$2.03 million6.45C$-9,371,678.00C($0.04)-1.40

Covalon Technologies has higher revenue and earnings than Naturally Splendid Enterprises. Covalon Technologies is trading at a lower price-to-earnings ratio than Naturally Splendid Enterprises, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Covalon Technologies and Naturally Splendid Enterprises, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Covalon Technologies0000N/A
Naturally Splendid Enterprises0000N/A

Profitability

This table compares Covalon Technologies and Naturally Splendid Enterprises' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Covalon TechnologiesN/AN/AN/A
Naturally Splendid EnterprisesN/AN/AN/A

Summary

Naturally Splendid Enterprises beats Covalon Technologies on 3 of the 5 factors compared between the two stocks.

Emerald Health Therapeutics (CVE:EMH) and Naturally Splendid Enterprises (CVE:NSP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Earnings and Valuation

This table compares Emerald Health Therapeutics and Naturally Splendid Enterprises' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million4.17C$-142,699,488.00C($0.70)-0.38
Naturally Splendid EnterprisesC$2.03 million6.45C$-9,371,678.00C($0.04)-1.40

Naturally Splendid Enterprises has lower revenue, but higher earnings than Emerald Health Therapeutics. Naturally Splendid Enterprises is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Emerald Health Therapeutics and Naturally Splendid Enterprises, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
Naturally Splendid Enterprises0000N/A

Profitability

This table compares Emerald Health Therapeutics and Naturally Splendid Enterprises' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
Naturally Splendid EnterprisesN/AN/AN/A

Summary

Naturally Splendid Enterprises beats Emerald Health Therapeutics on 3 of the 5 factors compared between the two stocks.

IntelGenx Technologies (CVE:IGX) and Naturally Splendid Enterprises (CVE:NSP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings & Valuation

This table compares IntelGenx Technologies and Naturally Splendid Enterprises' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.54 million47.84C$-7,274,150.00C($0.07)-10.15
Naturally Splendid EnterprisesC$2.03 million6.45C$-9,371,678.00C($0.04)-1.40

IntelGenx Technologies has higher earnings, but lower revenue than Naturally Splendid Enterprises. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Naturally Splendid Enterprises, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for IntelGenx Technologies and Naturally Splendid Enterprises, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IntelGenx Technologies0000N/A
Naturally Splendid Enterprises0000N/A

Profitability

This table compares IntelGenx Technologies and Naturally Splendid Enterprises' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IntelGenx TechnologiesN/AN/AN/A
Naturally Splendid EnterprisesN/AN/AN/A

Summary

Naturally Splendid Enterprises beats IntelGenx Technologies on 3 of the 5 factors compared between the two stocks.

Quest PharmaTech (CVE:QPT) and Naturally Splendid Enterprises (CVE:NSP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings & Valuation

This table compares Quest PharmaTech and Naturally Splendid Enterprises' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest PharmaTechC$38,871.00474.71C$109.88 millionC$0.660.17
Naturally Splendid EnterprisesC$2.03 million6.45C$-9,371,678.00C($0.04)-1.40

Quest PharmaTech has higher earnings, but lower revenue than Naturally Splendid Enterprises. Naturally Splendid Enterprises is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Quest PharmaTech and Naturally Splendid Enterprises, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest PharmaTech0000N/A
Naturally Splendid Enterprises0000N/A

Profitability

This table compares Quest PharmaTech and Naturally Splendid Enterprises' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest PharmaTechN/AN/AN/A
Naturally Splendid EnterprisesN/AN/AN/A

Summary

Quest PharmaTech beats Naturally Splendid Enterprises on 4 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Naturally Splendid Enterprises (CVE:NSP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings & Valuation

This table compares Ceapro and Naturally Splendid Enterprises' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$16.14 million3.80C$2.56 millionC$0.0323.94
Naturally Splendid EnterprisesC$2.03 million6.45C$-9,371,678.00C($0.04)-1.40

Ceapro has higher revenue and earnings than Naturally Splendid Enterprises. Naturally Splendid Enterprises is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Ceapro and Naturally Splendid Enterprises, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ceapro0000N/A
Naturally Splendid Enterprises0000N/A

Profitability

This table compares Ceapro and Naturally Splendid Enterprises' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CeaproN/AN/AN/A
Naturally Splendid EnterprisesN/AN/AN/A

Summary

Ceapro beats Naturally Splendid Enterprises on 4 of the 5 factors compared between the two stocks.

Crescita Therapeutics (TSE:CTX) and Naturally Splendid Enterprises (CVE:NSP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current ratings for Crescita Therapeutics and Naturally Splendid Enterprises, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crescita Therapeutics0000N/A
Naturally Splendid Enterprises0000N/A

Profitability

This table compares Crescita Therapeutics and Naturally Splendid Enterprises' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crescita TherapeuticsN/AN/AN/A
Naturally Splendid EnterprisesN/AN/AN/A

Earnings & Valuation

This table compares Crescita Therapeutics and Naturally Splendid Enterprises' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$15.64 million1.12C$41,296.00C$0.00425.00
Naturally Splendid EnterprisesC$2.03 million6.45C$-9,371,678.00C($0.04)-1.40

Crescita Therapeutics has higher revenue and earnings than Naturally Splendid Enterprises. Naturally Splendid Enterprises is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Crescita Therapeutics beats Naturally Splendid Enterprises on 4 of the 5 factors compared between the two stocks.


Naturally Splendid Enterprises Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
COV
Covalon Technologies
0.6$1.41flatC$37.44 millionC$23.84 million-5.92
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.27flatC$34.02 millionC$13.02 million-0.38
IGX
IntelGenx Technologies
0.9$0.66flatC$30.87 millionC$1.54 million-10.15High Trading Volume
News Coverage
QPT
Quest PharmaTech
0.8$0.11flatC$21.76 millionC$38,871.000.17High Trading Volume
Gap Down
CZO
Ceapro
0.6$0.79flatC$21.65 millionC$16.14 million23.94
CTX
Crescita Therapeutics
0.6$0.85flatC$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.16flatC$14.12 millionC$1.34 million-4.57
GSD
Devonian Health Group
0.5$0.27flatC$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09flatC$12.70 millionN/A-4.09
MPH
Medicure
0.7$1.60flatC$10.80 millionC$12.71 million-1.03Gap Up
BTI
Bioasis Technologies
0.7$0.44flatC$10.16 millionC$4.12 million40.00
HEM
Hemostemix
0.6$0.48flatC$9.07 millionN/A-2.86
ICO
iCo Therapeutics
0.5$0.11flatC$7.69 millionN/A-8.75News Coverage
IBT
IBEX Technologies
0.7$0.36flatC$6.94 millionC$5.60 million6.67
IOT
Innovotech
0.8$0.15flatC$6.52 millionC$1.04 million75.00
BCT
BriaCell Therapeutics
0.5$4.90flatC$4.48 millionN/A-1.58High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08flatC$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04flatC$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03flatC$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01flatC$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5$2.95flatC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.20
LTY
Liberty Biopharma
0.6$2.00flatC$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
SCYB
Scythian Biosciences
0.5$3.49flatC$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32flatC$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.